Hydrogen Gas Insufficiency in Mitigating Intestinal Mucosal Injury in NOMI Without Transmural Necrosis: A Critical Swine Model Assessment.
Raihan Mohammed Mohiuddin, Mohammed Misbah Ul Haq · Acute medicine & surgery · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In an animal model, the reported findings that hydrogen inhalation did not significantly mitigate histological ischemic injury in the absence of transmural necrosis are important, as they suggest that hydrogen therapy alone may not be sufficient for NOMI treatment. These preclinical findings add evidence about the molecular-hydrogen effects, outcomes, and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen was evaluated in this publication and summarizes the source-grounded findings below. The reported findings that hydrogen inhalation did not significantly mitigate histological ischemic injury in the absence of transmural necrosis are important, as they suggest that hydrogen therapy alone may not be sufficient for NOMI treatment.
What the Researchers Studied
The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Investigated hydrogen inhalation therapy in a swine model of non‐occlusive mesenteric ischemia (NOMI). The reported findings that hydrogen inhalation did not significantly mitigate histological ischemic injury in the absence of transmural necrosis are important, as they suggest that hydrogen therapy alone may not be sufficient for NOMI treatment. Translating this into clinical terms, the current findings should temper enthusiasm for hydrogen inhalation as a standalone therapy but should not dismiss its potential contribution as part of a multimodal approach, for example, combined with early vasodilator infusion or optimized hemodynamic support [ 3 ]. This opens the door for future investigations into whether hydrogen might synergize with other therapies in NOMI, particularly at later disease stages, where oxidative stress is more pronounced.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The study used a preclinical animal experiment.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.